POST EVENT REPORT IP Life Sciences Exchange 2015

Transcription

1 POST EVENT REPORT IP Life Sciences Exchange 2015 A vivid cross-section of present IP challenges, interwoven with opportunities to discuss present needs with solution providers. Deputy Head of IP Egis Pharmaceuticals Great programme covering some of the most current topics in IP. Assistant General Counsel Pfizer Inc. Great event offering good networking opportunities due to its unique format - industry specific, selected delegates, one-to-one meetings, good size and great facilities. Manager European Client Services Murgitroyd 44 (0) info@thelegalexchangenetwork.com

2 Post Event Report CONTENTS Welcome Page 3 The event in numbers Page 4 Key attendance statistics Page 5 Delegate investment priorities Page IP Life Sciences session highlights Page 8 What did your peers really think? Page 9 With thanks to our partners Page 10 The 2016 speaker panel Page 11 How to get involved in a future Exchange meeting Page 12

3 WELCOME IP Life Sciences Exchange (IPLS) 2015 arrived at a critical time for the industry, with landmark decisions and IP developments emerging daily from the pan- European framework. IPLS explored a range of crucial issues, including strategic planning to protect patents whilst engaging in the UPC, pathways to bringing generic drugs to the US market, integration of biosimilars and navigating new perimeters in patentable products influenced by key case law. In particular, IPLS focused on how such issues interacted with pharmaceuticals, biotechnology and chemicals companies. After all, these issues are critical components of an industry where Life Sciences companies are keen to protect innovation and retain their competitive advantage. To address the challenges that come with protecting innovation and retaining competitive advantage, we brought together 50 CIPOs, Heads, Directors and VPs of IP and Patent for a packed two days of BrainWeave s, group discussions, business meetings and informal networking opportunities. Building on the success of our annual crossindustry Global IP Exchange, this forum of senior IP leaders was a great opportunity to share experiences and projects from across pharmaceuticals, biotechnology and chemicals. This report will offer you an insight into the key themes and takeaways from the Exchange, as well an exclusive look at what is happening in the industry.

4 IP LIFE SCIENCES EXCHANGE IN STATS DELEGATES 80% of delegates had global responsibility 81% of delegates had a personal annual budget of 500, % of delegates annual company revenue was 1 billion + Delegates came from 16 different countries 78% of delegates comprised VP, Director, Head, General Counsel or CIPO job titles 100% of attendees ranked the speakers as Excellent, Very Good or Good WHO ATTENDED IN 2016? INDUSTRY 26.32% 26.32% 23.68% 15.79% 7.89% Pharmaceuticals (Big) Pharmaceuticals (Medium) Pharmaceuticals (Small) Biotechnology Chemicals (Other) FUNCTIONAL RESPONSIBILITY Across All IP Disciplines 46.32% Patents 12.1% Patent, Licensing, Litigation 27.9% Trademark, Brand Protection, Anti-Counterfeiting 9.47% Licensing & Monetisation 4.21%

5 GLOBAL REACH REGIONAL RESPONSIBILITY GEOGRAPHY Global 71.05% Europe + USA 10.52% Emerging Markets 5.26% Europe 13.16% SWITZERLAND 15.79% UK 13.16% ISRAEL 10.53% FRANCE 7.89% THE NETHERLANDS 7.89% USA 5.26% GERMANY 5.26% IRELAND 5.26% SWEDEN 5.26% SPAIN 5.26% ITALY 5.26% MALAYSIA 2.63% POLAND 2.63% FINLAND 2.63% DENMARK 2.63% BUDAPEST 2.63%

6 WHAT ARE THE DELEGATES PLANNING TO INVEST IN DURING ? Investment Category % of Delegates planning investment within 6-12 months of the Exchange IP Due Diligence 63.64% Patent Litigation 57.58% Licensing 57.58% Competitive Research and Analysis 48.48% Literature and Prior Art Search 45.45% Patent Portfolio Management Tools 45.45% Valuation Services 45.45% IP Strategy & Innovation Consultants 42.42% Legal Spend Management 39.39% IP Investigations 36.36% Patent Renewals Management 33.33% Integrated IP Management Software 27.27% Trademark Litigation 27.27% IP Insurance Service 27.27% Brand Monitoring 24.24% Monetization Consultants 21.21% Broker Services 18.18% Translation Services 18.18%

7 WHAT ARE DELEGATES TOP PROBLEMS IN ? Freedom To Operate in locations less well defined, like Russia, Australia, South Korea and Brazil Cost efficient management of IP portfolio to take care of annual payments for patents and applications IP Monetisation for patents not in use: not right for internal commercialisation but could be good for external licensing UPC: Learning and keeping up to date with impending rules, fees and strategies Buy in to ensure agreement from all parties on our objectives Competitive analysis to track what others are doing Contract management and royalties payment management tools to deal with licensing terms IP litigation strategy in Europe, US & South America Strategies to get into new markets, especially emerging markets, in order to mitigate risk

8 2016 IP LIFE SCIENCES EXCHANGE SESSION HIGHLIGHTS ENFORCEMENT AND PROTECTION IP Enforcement Challenges in Emerging Markets Gabriel Kleiman, Assistant General Counsel, Pfizer Inc. Gabriel focused attendees attention on five points throughout his global IP enforcement presentation: Have you considered the following when enforcing your patents in emerging economies? Will your patent be granted? If so, will it have sufficient scope to cover your product? Is your patent a reliable property right? Will you be able to enforce your patent? If you lose an enforcement action, have you considered whether there would there be negative consequences? CASE LAW DEVELOPMENTS Navigating New Perimeters in Patentable Products Influenced by Key Case Law: Stem Cells Dr Ian Bryan, Senior IP Counsel, GE Healthcare Life Sciences Ian focused on the potential of stem cells and ultimately what is patentable in stem cell innovations across Europe. In noting key case law such as Enlarged Board of Appeal (EBA): G2/06 Stem Cells/WARF, Ian ultimately concluded that: Inventions based on adult stem cells are patentable hesc based inventions based on parthenogenesis after 5 June 2003* are patentable hesc based inventions on Single Cell Blastomere Biopsy after 10 January 2008** are patentable Induced pluripotent stem cell based inventions are patentable hesc inventions exclusively necessitating human embryo destruction are NOT patentable LITIGATION Mapping the Pathway to Successfully Conducting Multijurisdictional Litigation Dr.Toni Santamaria, Head of IP, Europe, Accord Toni s session was of strategic interest to those delegates involved in multijurisdictional litigation. In particular, Toni suggested successful litigation rested on your team, commercial goals and strategy and had to consider the following: Plan strategy but be ready to change the plans Align IP with business interests Consider all the costs and risks involved Appoint the best possible team

9 Very interesting and professional. The mix between talks, round tables, and personal meetings was very good. Intellectual Property Director, Life Sciences, B.G. Negev Technologies and Applications Ltd. Very interesting and relevant. I got the impression that particularly on the first day many issues were addressed with which many IP counsels have to deal at present. IP Counsel Vifor Pharma Very intense. Interesting topics and interesting people-providers. Chief IP Officer AB-Bioticsm A good opportunity to meet likeminded professionals and keep up to date with the field. IP Manager Enigma Diagnostics It was great to meet with colleagues in the field and get everyone's perspective on important impending changes and developments in the legislative arena as well from the courts. Sr VP IP ProQR Therapeutics Really was a good forum to exchange common challenges and possible solutions. VP IP Neurology/ Neurotoxin Ipsen Pharma

10 MANY THANKS TO OUR 2015 SPONSORS AND MEDIA PARTNERS Sponsors HGF Media Partners

11 MANY THANKS TO OUR FANTASTIC 2015 SPEAKER PANEL IP Life Sciences Exchange Speakers Included: Roya Ghafele Director, OxFirst Ltd. and Fellow St Cross College, Oxford Bernd Hutter Head of IP MorphoSys AG Gabe Kleiman Assistant General Counsel Pfizer Henrik Mathiassen Head of Patent Department Zealand Pharma Seth Fidel Lead IP Counsel Merrimack Pharma Jürgen Dressel Head Global Patent Litigation Strategy Novartis Pharma Toni Santamaria Head of Intellectual Property, Europe Accord Healthcare Ian Bryan IP Counsel GE Health Care Alexander Ramsay Vice Chairman UPC Harry Kraft Senior Patent Attorney Ablynx Anna Coleman Senior Counsel Teva Pharmaceuticals

12 JOIN US IN 2016! November 2016, Germany The 2nd IP Life Sciences Exchange will bring together 80 senior IP decision makers plus hand-selected solution providers for two days of interactive networking and senior level benchmarking. This popular invitation only meeting is open to Chief IP Officers, General Counsel, VPs, Directors and Heads of IP and Patents who want to drive their IP strategy to success. Discover what strategies and solutions innovative companies are adopting Develop new business partnerships through a range of interactive networking opportunities Participate in intimate working groups with senior peers to help overcome common challenges and develop new strategies To ensure that you are in the best position to implement proven solutions to your daily challenges, IPLS continues to be delivered by the highest ranked experts within the Life Sciences community. The IP Life Sciences Exchange is the must-attend event in the Life Sciences calendar. Request your invitation

13 LEGAL EVENT PORTFOLIO Global IP Exchange March, Germany Global IP Exchange US December, San Diego Corporate Counsel & Compliance Exchange April, London UK Pat-Tech Exchange June, Dublin, Ireland Information Governance Exchange June, Atlanta, Georgia, USA Corporate Counsel Exchange October, Germany IP Life Sciences Exchange November, Germany Corporate Counsel Exchange Financial Services December, London, UK